About
Dr. Scott Gottlieb was appointed a UnitedHealth Group director in November 2025 and serves on the Health and Clinical Practice Policies and Public Responsibility Committees. He served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019 and is a Senior Fellow at the American Enterprise Institute and a Special Partner at New Enterprise Associates, and also serves as a director of Pfizer, Tempus AI and Illumina.
Roles
Unitedhealth Group Inc.
Independent Director · Current role
2025–present
American Enterprise Institute
Senior Fellow
2019–Present
New Enterprise Associates
Special Partner
2019–Present
U.S. Food and Drug Administration
Commissioner
2017–2019
U.S. Food and Drug Administration
Deputy Commissioner for Medical and Scientific Affairs
2005–2007
U.S. Food and Drug Administration
Director of Medical Policy Development
2004
U.S. Food and Drug Administration
Senior Advisor to the Commissioner for Medical Technology
2003–2004
External Roles
Pfizer, Inc.
Director
—
Tempus AI, Inc.
Director
—
Illumina, Inc.
Director
—
Director Compensation
FY 2025Fees earned or paid in cash
$0
Payment scheduleAnnual cash retainer
Additional detailsElected to convert cash fees into deferred stock units / shares
Stock awards
$42,050
Additional detailsAnnual equity retainer (grant-date fair value)
NoteAppointed to the Board on November 18, 2025 (partial-year compensation).
Total
$42,050
Fiscal year2025
Also at Unitedhealth Group Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.